Targeted Therapy for Biliary Tract Cancer

Cancers - Tập 3 Số 2 - Trang 2243-2254
Junji Furuse1, Takuji Okusaka2,3
1Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan
2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
3Kyorin university

Tóm tắt

It is necessary to establish effective chemotherapy to improve the survival of patients with biliary tract cancer, because most of these patients are unsuitable candidates for surgery, and even patients undergoing curative surgery often have recurrence. Recently, the combination of cisplatin plus gemcitabine was reported to show survival benefits over gemcitabine alone in randomized clinical trials conducted in the United Kingdom and Japan. Thus, the combination of cisplatin plus gemcitabine is now recognized as the standard therapy for unresectable biliary tract cancer. One of the next issues that need to be addressed is whether molecular targeted agents might also be effective against biliary tract cancer. Although some targeted agents have been investigated as monotherapy for first-line chemotherapy, none were found to exert satisfactory efficacy. On the other hand, monoclonal antibodies such as bevacizumab and cetuximab have also been investigated in combination with a gemcitabine-based regimen and have been demonstrated to show promising activity. Furthermore, clinical trials using new targeted agents for biliary tract cancer are also proposed. This cancer is a relatively rare and heterogeneous tumor consisting of cholangiocarcinoma and gallbladder carcinoma. Therefore, a large randomized clinical trial is necessary to confirm the efficacy of chemotherapy, and international collaboration is important.

Từ khóa


Tài liệu tham khảo

Randi, 2009, Epidemiology of biliary tract cancers: An update, Ann. Oncol., 20, 146, 10.1093/annonc/mdn533

Lazaridis, 2005, Cholangiocarciinoma, Gastroenterology, 128, 1655, 10.1053/j.gastro.2005.03.040

Aljiffry, 2009, Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009, World J. Gastroenterol., 15, 4240, 10.3748/wjg.15.4240

2007, Risk factors for cholangiocarcinoma, Eur. J. Gastroenterol. Hepatol., 19, 615, 10.1097/MEG.0b013e328224b935

Gallardo, 2001, A phase II study of gemcitabine in gallbladder carcinoma, Ann. Oncol., 12, 1403, 10.1023/A:1012543223020

Penz, 2001, Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer, Ann. Oncol., 12, 183, 10.1023/A:1008352123009

Tsavaris, 2004, Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest, New. Drugs., 22, 193, 10.1023/B:DRUG.0000011797.09549.53

Okusaka, 2006, Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer, Cancer Chemother. Pharmacol., 57, 647, 10.1007/s00280-005-0095-3

Furuse, 2008, S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study, Cancer Chemother. Pharmacol., 62, 849, 10.1007/s00280-007-0673-7

Doval, 2004, A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer, Br. J. Cancer, 90, 1516, 10.1038/sj.bjc.6601736

Thongprasert, 2005, Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma, Ann. Oncol., 16, 279, 10.1093/annonc/mdi046

Kim, 2006, A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer, Cancer, 106, 1339, 10.1002/cncr.21741

Tournigand, 2004, Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study, Ann. Oncol., 15, 1339, 10.1093/annonc/mdh351

Harder, 2006, Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer, Br. J. Cancer, 95, 848, 10.1038/sj.bjc.6603334

Fartoux, 2008, Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study, Br. J. Cancer, 99, 862, 10.1038/sj.bjc.6604628

Kim, 2009, A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer, Cancer Chemother. Pharmacol., 64, 371, 10.1007/s00280-008-0883-7

Jang, 2010, Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial, Cancer Chemother. Pharmacol., 65, 641, 10.1007/s00280-009-1069-7

Knox, 2005, Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial, J. Clin. Oncol., 23, 2332, 10.1200/JCO.2005.51.008

Cho, 2005, Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma, Cancer, 104, 2753, 10.1002/cncr.21591

Riechelmann, 2007, Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer, Cancer, 110, 1307, 10.1002/cncr.22902

Koeberle, 2008, Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research, J. Clin. Oncol., 26, 3702, 10.1200/JCO.2008.16.5704

Sasaki, 2010, Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer, Cancer Chemother. Pharmacol., 65, 1101, 10.1007/s00280-009-1115-5

Furuse, 2008, Guidelines for chemotherapy of biliary tract and ampullary carcinomas, J. Hepatobiliary Pancreat. Surg., 15, 55, 10.1007/s00534-007-1280-z

Valle, 2010, Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N. Engl. J. Med., 362, 1273, 10.1056/NEJMoa0908721

Okusaka, 2010, Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan, Br. J. Cancer, 103, 469, 10.1038/sj.bjc.6605779

Sharma, 2010, Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study, J. Clin. Oncol., 28, 4581, 10.1200/JCO.2010.29.3605

Thomas, 2007, Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy, Crit. Rev. Oncol. Hematol., 61, 44, 10.1016/j.critrevonc.2006.07.006

Nonomura, 1988, Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method, Liver, 8, 157, 10.1111/j.1600-0676.1988.tb00985.x

Yoshikawa, 2008, Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma, Br. J. Cancer, 98, 418, 10.1038/sj.bjc.6604129

Nakazawa, 2005, Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers, J. Pathol., 206, 356, 10.1002/path.1779

Hitre, 2009, Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, N. Engl. J. Med., 360, 1408, 10.1056/NEJMoa0805019

Yoshikawa, 2009, Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma, Br. J. Cancer, 100, 1257, 10.1038/sj.bjc.6604988

Philip, 2006, Phase II study of erlotinib in patients with advanced biliary cancer, J. Clin. Oncol., 24, 3069, 10.1200/JCO.2005.05.3579

Ramanathan, 2009, A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer, Cancer Chemother. Pharmacol., 64, 777, 10.1007/s00280-009-0927-7

Gruenberger, 2010, Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study, Lancet Oncol., 11, 1142, 10.1016/S1470-2045(10)70247-3

Malka, D., Trarbach, T., Fartoux, L., Mendiboure, J., de la Fouchardière, C., Viret, F., Assenat, E., Boucher, E., Rosmorduc, O., and Greten, T. (2009). A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J. Clin. Oncol, 27, Abstr. 4520.

Tong, 2004, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors, Cancer Res., 64, 3731, 10.1158/0008-5472.CAN-04-0074

Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819

Gerber, 2005, Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies, Cancer Res., 65, 671, 10.1158/0008-5472.671.65.3

Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N. Engl. J. Med., 359, 378, 10.1056/NEJMoa0708857

El-Khoueiry, A.B., Rankin, C., Lenz, H.J., Philip, P., Rivkin, S. E., and Blanke, C. D. (2007). SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J. Clin. Oncol., 25, Abstr. 4639.

Bengala, 2010, Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial, Br. J. Cancer, 102, 68, 10.1038/sj.bjc.6605458

Zhu, 2010, Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: A phase 2 study, Lancet Oncol., 11, 48, 10.1016/S1470-2045(09)70333-X

Lubner, 2010, Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study, J. Clin. Oncol., 28, 3491, 10.1200/JCO.2010.28.4075

Nagakawa, 2002, Biliary tract cancer treatment: results from the biliary tract cancer statistics registry in Japan, J. Hepatobiliary Pancreat. Surg., 9, 569, 10.1007/s005340200076

Yonemoto, 2007, A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer, Jpn. J. Clin. Oncol., 37, 843, 10.1093/jjco/hym116

Thông tin
Thông tin xuất bản

Cancers

Tập 3 Số 2

2243-2254

Thông tin tác giả